
1. j viral hepat. 2017 jan;24(1):13-16. doi: 10.1111/jvh.12651. epub 2016 dec 1.

secondary prophylaxis hepatocellular carcinoma: comparison of
direct-acting antivirals pegylated interferon untreated cohort.

vukotic r(1), di donato r(1), conti f(1), scuteri a(1), serra c(2), andreone
p(1).

author information: 
(1)dipartimento di scienze mediche e chirurgiche, centro di ricerca per lo studio
delle epatiti, università degli studi di bologna, bologna, italy.
(2)dipartimento delle insufficienze d'organo e dei trapianti, azienda
ospedaliero-universitaria di bologna, policlinico s. orsola-malpighi, bologna,
italy.

during past two decades, several studies showed reduced rates of
hepatocellular carcinoma recurrence patients hcv-related cirrhosis 
interferon-based antiviral therapies respect untreated controls, even without 
reaching viral clearance. recent development new all-oral regimens with
direct-acting antivirals radically improved therapeutic management of
hepatitis c. nevertheless, paradoxical, least unexpected, high rates of
both occurrence recurrence hepatocellular carcinoma treatment with
direct-acting antivirals, reported recent literature. these
findings generated strong rebound hepatology community at
present still controversial. sought compare hepatocellular carcinoma
recurrence-free survival historical cohort treated pegylated
interferon/ribavirin untreated cohort cohort treated with
direct-acting antivirals.

© 2016 john wiley & sons ltd.

doi: 10.1111/jvh.12651 
pmid: 27905669  [indexed medline]

